Canaccord Adams reiterates a 'Buy' rating on Optimer Pharmaceuticals (Nasdaq: OPTR), increases price target from $12 to $14.

Canaccord ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE